Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433822 | 0.73 | KDM4E (0.54) | KDM4EALDH1A1POLBHSP90AA1KMT2A | |
| SCHEMBL22614908 | 0.72 | ALDH1A1 (0.37) | KDM4EALDH1A1POLBHSP90AA1 | |
| SCHEMBL22423157 | 0.68 | — | — | |
| SCHEMBL3447768 | 0.66 | KMT2A (0.45) | KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL13591803 | 0.64 | KDM4E (0.54) | KDM4EALDH1A1POLBHSP90AA1CDK5 | |
| SCHEMBL9766381 | 0.58 | DYRK1A (0.38) | KDM4EALDH1A1POLBHSP90AA1MAPT | |
| SCHEMBL15740449 | 0.57 | DHFR (0.43) | KMT2A | |
| SCHEMBL342514 | 0.57 | ALDH1A1 (0.44) | ALDH1A1CLK1CDK5CDK5R1 | |
| SCHEMBL24496130 | 0.55 | HRH4 (0.34) | — | |
| SCHEMBL16684759 | 0.53 | KDM4E (0.31) | KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020223469-A1 | N-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)-4,5-DI HYDRO-1H-IMIDAZO[4,5-H]QUINAZOLIN-8-AMINE DERIVATIVES AND RELATED COMPOUNDS AS CYCLIN-DEPENDENT KINASE 2 (CDK2) INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |